Amazon Pharmacy has launched a GLP-1 delivery service for eligible Medicare patients, offering Wegovy, Zepbound KwikPen, and Foundayo at $50 per month with free home delivery. The service runs through the CMS Medicare GLP-1 Bridge Program, which lasts until December 31, 2027. Amazon handles…
Amazon Pharmacy has begun distributing GLP-1 weight management medications to eligible Medicare patients at a flat cost of $50 per month, with free home delivery included. The product lineup covers Wegovy in both injectable and oral pill forms, the Zepbound KwikPen, and Foundayo. These treatments are being offered through a newly introduced Amazon One Medical weight management program that combines primary care, pharmacy, and virtual care options, allowing patients to address obesity as a chronic condition in one place.
The medicines are being supplied under the Medicare GLP-1 Bridge Program, a short-term federal initiative run by CMS that extends through December 31, 2027. The program gives eligible Medicare Part D members who meet specific clinical criteria access to weight management prescriptions at a predictable and accessible price. Amazon says many claims submitted so far have already resulted in complete orders, with patients receiving their medications quickly and without administrative burden.
Cost has historically kept many Medicare patients from reaching GLP-1 therapies. With the Bridge Program removing that barrier, Amazon Pharmacy says it is focusing on the friction that remains: confusing paperwork, prior authorization delays, and long waits at the pharmacy counter. The company's operational workflow shifts the administrative burden to the pharmacy, which means the pharmacy handles benefit verification, prior authorization, and enrollment initiation once a clinician submits an electronic prescription.
When a clinician sends an electronic GLP-1 prescription to Amazon Pharmacy, patients can add their Bridge insurance plan and Medicare details to their Amazon Pharmacy account. From that point, Amazon says it manages the remaining steps, including eligibility verification, prior authorization, and starting the enrollment process on the patient's behalf. Patients do not need to navigate enrollment steps, chase down approvals, or wait at a counter.
"We want to make sure nothing stands in the way, no confusing paperwork, no prior authorization delays, no waiting at a pharmacy counter," said Tanvi Patel, vice president and general manager of Amazon Pharmacy. "Once a patient's clinician sends the prescription, we take care of the rest and deliver their medication to their door."
The service is designed to treat obesity as a chronic condition rather than a single prescription event. By uniting primary care, pharmacy, and virtual care within the Amazon One Medical weight management program, the company aims to give patients a single destination for their weight management needs. The Bridge Program pricing of $50 per month holds through 2027, giving beneficiaries a defined price point while the federal initiative remains active.
Amazon says the workflow hands the administrative load to the pharmacy so patients do not have to coordinate between their clinician, their insurer, and their pharmacy. Once the prescription is transmitted electronically, the patient's main tasks are adding insurance details and waiting for delivery. The company describes this as a way to remove the friction that has historically delayed Medicare patients' access to GLP-1 medications.
Eligible patients have several ways to receive their medications. Free home delivery is available nationwide, and same-day delivery is offered in more than 3,100 U.S. cities and towns, with no Prime membership required. Amazon says same-day delivery will expand to nearly 4,500 cities and towns by the end of 2026.
Patients can also choose in-office pickup at Amazon Pharmacy kiosks located at select One Medical locations, where the newly approved oral versions of Wegovy and Foundayo are dispensed. Amazon Pharmacy provides 24/7 access to licensed pharmacists, which gives patients a direct line for questions about their medications. Caregiver support is also available, allowing a trusted individual to manage medications on behalf of a loved one through their own Amazon account, a feature intended to improve medication management continuity for older adults and dependent beneficiaries.
The kiosk pickup option covers certain oral agents, while injectable products such as the Zepbound KwikPen are delivered to the patient's home. Same-day delivery does not require a Prime membership, and the company notes that delivery coverage will keep growing as it expands to nearly 4,500 cities and towns by the end of 2026. These distribution options are meant to reduce the waiting and travel that patients have sometimes faced when filling GLP-1 prescriptions at traditional pharmacies.
For beneficiaries who need help beyond their own account, the caregiver support feature is a notable addition. A trusted individual can manage medications through their own Amazon account, which can be especially useful for older adults. Amazon Pharmacy also maintains round-the-clock pharmacist availability to answer clinical questions whenever they arise.
The $50 monthly price is paired with additional affordability measures. Amazon Pharmacy automatically applies manufacturer coupons at checkout, and it offers transparent pricing and availability visibility so patients can see costs before committing. The company reports cumulative savings exceeding $300 million from these measures.
Amazon Pharmacy says it plans to continue building out access points while the Bridge Program runs through the end of 2027. Same-day delivery coverage is expanding, and the company intends to keep adding kiosk pickup locations and pharmacist support. The stated goal is to reduce the administrative steps that have historically slowed Medicare patients' access to GLP-1 therapies.
The company announced the launch on August 6, 2026, and CMS published details about the Medicare GLP-1 Bridge Program on July 13, 2026. With the program's timeline set through December 31, 2027, Amazon expects to keep refining the service, including enrollment handling, delivery reach, and pharmacist support, for the duration of the federal initiative.
Peptides referenced: Semaglutide, Tirzepatide, GLP-1.
Related reading: Novo Nordisk CFO Covers Oral Wegovy Rollout and Beyond, Postbiotic Supplement Boosts Body's Own GLP-1 and Weight Loss, Claims Data Lend Support to Tirzepatide's CV Effects in Diabetes, No Link Between GLP-1 and Hypertensive Disorders of Pregnancy.